227 related articles for article (PubMed ID: 22986143)
1. Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM
Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
Yao H; Li N; Yuan H
BMC Cancer; 2022 Dec; 22(1):1337. PubMed ID: 36544182
[TBL] [Abstract][Full Text] [Related]
3. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.
Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG
PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765
[TBL] [Abstract][Full Text] [Related]
4. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
[TBL] [Abstract][Full Text] [Related]
5. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
[TBL] [Abstract][Full Text] [Related]
6. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
[TBL] [Abstract][Full Text] [Related]
7. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Song H; Dicks E; Ramus SJ; Tyrer JP; Intermaggio MP; Hayward J; Edlund CK; Conti D; Harrington P; Fraser L; Philpott S; Anderson C; Rosenthal A; Gentry-Maharaj A; Bowtell DD; Alsop K; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Høgdall E; Høgdall CK; Jensen A; Kjaer SK; Lubiński J; Huzarski T; Jakubowska A; Gronwald J; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Odunsi K; Goode EL; Menon U; Jacobs IJ; Gayther SA; Pharoah PD
J Clin Oncol; 2015 Sep; 33(26):2901-7. PubMed ID: 26261251
[TBL] [Abstract][Full Text] [Related]
8. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Loveday C; Turnbull C; Ramsay E; Hughes D; Ruark E; Frankum JR; Bowden G; Kalmyrzaev B; Warren-Perry M; Snape K; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; ; Eccles D; Evans DG; Renwick A; Seal S; Lord CJ; Ashworth A; Reis-Filho JS; Antoniou AC; Rahman N
Nat Genet; 2011 Aug; 43(9):879-882. PubMed ID: 21822267
[TBL] [Abstract][Full Text] [Related]
10. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families.
Osher DJ; De Leeneer K; Michils G; Hamel N; Tomiak E; Poppe B; Leunen K; Legius E; Shuen A; Smith E; Arseneau J; Tonin P; Matthijs G; Claes K; Tischkowitz MD; Foulkes WD
Br J Cancer; 2012 Apr; 106(8):1460-3. PubMed ID: 22415235
[TBL] [Abstract][Full Text] [Related]
13. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Walsh T; Casadei S; Lee MK; Pennil CC; Nord AS; Thornton AM; Roeb W; Agnew KJ; Stray SM; Wickramanayake A; Norquist B; Pennington KP; Garcia RL; King MC; Swisher EM
Proc Natl Acad Sci U S A; 2011 Nov; 108(44):18032-7. PubMed ID: 22006311
[TBL] [Abstract][Full Text] [Related]
14. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
15. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
16. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Suszynska M; Ratajska M; Kozlowski P
J Ovarian Res; 2020 May; 13(1):50. PubMed ID: 32359370
[TBL] [Abstract][Full Text] [Related]
17. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.
Soukupová J; Lhotová K; Janatová M; Kleiblová P; Vočka M; Foretová L; Zikán M; Kleibl Z
Klin Onkol; 2021; 34(1):26-32. PubMed ID: 33657816
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM
Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747
[TBL] [Abstract][Full Text] [Related]
20. BRCA2 germline mutations in primary cancer of the fallopian tube.
Casarsa S; Puglisi F; Baudi F; De Paola L; Venuta S; Piga A; Di Loreto C; Marchesoni D; D'Elia AV; Damante G
Oncol Rep; 2004 Aug; 12(2):313-6. PubMed ID: 15254695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
